Senseonics (NYSE:SENS) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of Senseonics (NYSE:SENS) in a research report issued to clients and investors on Friday. The brokerage set a “sell” rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $2.00 target price on shares of Senseonics in a report on Wednesday, August 14th.

Senseonics Trading Up 6.3 %

SENS opened at $0.35 on Friday. The firm has a market cap of $189.38 million, a price-to-earnings ratio of -2.72 and a beta of 0.79. The company has a quick ratio of 2.89, a current ratio of 3.11 and a debt-to-equity ratio of 59.17. The business’s 50 day moving average is $0.36 and its two-hundred day moving average is $0.40. Senseonics has a 52 week low of $0.32 and a 52 week high of $0.75.

Senseonics (NYSE:SENS) last released its earnings results on Thursday, August 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.03). The business had revenue of $4.87 million for the quarter, compared to analyst estimates of $4.86 million. Senseonics had a negative return on equity of 299.69% and a negative net margin of 335.15%. On average, research analysts predict that Senseonics will post -0.13 EPS for the current year.

Hedge Funds Weigh In On Senseonics

Institutional investors have recently made changes to their positions in the stock. State Board of Administration of Florida Retirement System acquired a new position in Senseonics in the first quarter valued at $91,000. GSA Capital Partners LLP acquired a new stake in Senseonics during the third quarter worth about $117,000. Virtu Financial LLC acquired a new stake in Senseonics during the first quarter worth about $162,000. Symmetry Partners LLC acquired a new stake in Senseonics during the third quarter worth about $164,000. Finally, Cubist Systematic Strategies LLC increased its stake in Senseonics by 25.9% during the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after acquiring an additional 85,501 shares during the last quarter. 12.36% of the stock is owned by institutional investors and hedge funds.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.